Next Article in Journal
Unlocking Therapeutic Potential of Novel Thieno-Oxazepine Hybrids as Multi-Target Inhibitors of AChE/BChE and Evaluation Against Alzheimer’s Disease: In Vivo, In Vitro, Histopathological, and Docking Studies
Next Article in Special Issue
Monoamine Oxidase Inhibitors in Drug Discovery Against Parkinson’s Disease: An Update
Previous Article in Journal
Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic Landscape
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Analytical Biomarkers for Inflammation Status Monitoring of Psychotropic and Antiepileptic Drugs

by
Wiktoria Jiers
1,2,*,
Karina Sommerfeld-Klatta
1,
Mehmet Gumustas
3,
Paul Mozdziak
4,
Magdalena Łukasik-Głębocka
5,
Artur Teżyk
6,
Zbigniew Żaba
5,
Czesław Żaba
6 and
Hanna Piotrowska-Kempisty
1,7,8
1
Department of Toxicology, Poznań University of Medical Sciences, 3 Rokietnicka Street, 60-631 Poznań, Poland
2
Doctoral School, Poznań University of Medical Sciences, 70 Bukowska Street, 60-812 Poznań, Poland
3
Institute of Forensic Sciences, Department of Forensic Toxicology, Ankara University, Balkiraz, Mamak Cd.6 A, Mamak, Ankara 06620, Turkey
4
Prestige Department of Poultry Science, College of Agriculture and Life Sciences, North Carolina State University, Raleigh, NC 27695, USA
5
Department of Emergency Medicine, Poznań University of Medical Sciences, 7 Rokietnicka Street, 60-806 Poznań, Poland
6
Department of Forensic Medicine, Poznań University of Medical Sciences, 10 Rokietnicka Street, 60-806 Poznań, Poland
7
Department of Basic and Preclinical Sciences, Institute of Veterinary Medicine, Nicolaus Copernicus University in Torun, 87-100 Torun, Poland
8
Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibres and Medicinal Plants, Kolejowa 2, 62-064 Plewiska, Poland
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2025, 18(8), 1213; https://doi.org/10.3390/ph18081213
Submission received: 11 July 2025 / Revised: 7 August 2025 / Accepted: 14 August 2025 / Published: 17 August 2025
(This article belongs to the Special Issue Potential Pharmacotherapeutic Targets in Neurodegenerative Diseases)

Abstract

In recent years, an increasing amount of research has investigated the impact of chronic inflammation on the development and progression of both neurological and psychiatric disorders, including epilepsy, depression, schizophrenia, and bipolar disorder. Moreover, growing attention is being paid to how inflammatory processes contribute to disease mechanisms, influence symptom severity, and interact with pharmacological treatments in these conditions. Changes in the levels of inflammatory biomarkers, such as cytokines and C-reactive protein, may signal the early stages of neurological disorder development. Furthermore, specific biomarker profiles have been identified for individual diseases, and chronic treatment may affect their blood levels. Over the last two decades, significant progress in the study of inflammatory biomarkers in psychiatric disorders and epilepsy has been achieved, demonstrating an association between biomarkers with symptoms, a potential prognostic role, and possible use in personalising therapy. Furthermore, widely used methods for biomarker evaluation, such as immunoenzymatic assays and flow cytometry, remain essential tools for current research. Despite numerous indications of the importance of inflammation in psychiatry and neurology, the available studies are characterised by considerable heterogeneity in terms of both population selection and methodology. Based on the available data, inflammatory biomarkers represent a promising diagnostic and therapeutic tool for epilepsy and psychiatric disorders. Although existing studies suggest a correlation between inflammation and the symptoms of various disorders, inconsistent results highlight the need for further research to enable wider implementation of these findings in psychiatric and epilepsy practice. Advancing knowledge of inflammatory biomarkers is essential for improving treatment outcomes and promoting the development of targeted interventions.
Keywords: inflammation; psychotropic and antiepileptic drugs; biomarkers; anti-inflammatory treatment inflammation; psychotropic and antiepileptic drugs; biomarkers; anti-inflammatory treatment
Graphical Abstract

Share and Cite

MDPI and ACS Style

Jiers, W.; Sommerfeld-Klatta, K.; Gumustas, M.; Mozdziak, P.; Łukasik-Głębocka, M.; Teżyk, A.; Żaba, Z.; Żaba, C.; Piotrowska-Kempisty, H. Analytical Biomarkers for Inflammation Status Monitoring of Psychotropic and Antiepileptic Drugs. Pharmaceuticals 2025, 18, 1213. https://doi.org/10.3390/ph18081213

AMA Style

Jiers W, Sommerfeld-Klatta K, Gumustas M, Mozdziak P, Łukasik-Głębocka M, Teżyk A, Żaba Z, Żaba C, Piotrowska-Kempisty H. Analytical Biomarkers for Inflammation Status Monitoring of Psychotropic and Antiepileptic Drugs. Pharmaceuticals. 2025; 18(8):1213. https://doi.org/10.3390/ph18081213

Chicago/Turabian Style

Jiers, Wiktoria, Karina Sommerfeld-Klatta, Mehmet Gumustas, Paul Mozdziak, Magdalena Łukasik-Głębocka, Artur Teżyk, Zbigniew Żaba, Czesław Żaba, and Hanna Piotrowska-Kempisty. 2025. "Analytical Biomarkers for Inflammation Status Monitoring of Psychotropic and Antiepileptic Drugs" Pharmaceuticals 18, no. 8: 1213. https://doi.org/10.3390/ph18081213

APA Style

Jiers, W., Sommerfeld-Klatta, K., Gumustas, M., Mozdziak, P., Łukasik-Głębocka, M., Teżyk, A., Żaba, Z., Żaba, C., & Piotrowska-Kempisty, H. (2025). Analytical Biomarkers for Inflammation Status Monitoring of Psychotropic and Antiepileptic Drugs. Pharmaceuticals, 18(8), 1213. https://doi.org/10.3390/ph18081213

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop